导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.86% | 1975/4773 |
| 近一周 | -0.05% | 890/5465 |
| 近一月 | 5.05% | 66/5421 |
| 近一季 | 5.70% | 298/5231 |
| 近半年 | 4.98% | 828/4920 |
| 近一年 | 3.51% | 2059/4394 |
| 近两年 | 37.82% | 1996/2954 |
| 近三年 | 46.48% | 629/2253 |
| 成立以来 | 148.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.67% 2859/4961 |
-8.16% 3849/5312 |
- - |
- - |
| 2025 | 9.90% 2845/4813 |
2.41% 1383/3635 |
11.32% 191/4076 |
-8.44% 4036/4524 |
5.28% 456/4813 |
| 2024 | 38.75% 34/3463 |
9.91% 102/2808 |
6.80% 129/3014 |
12.16% 2402/3129 |
5.39% 611/3463 |
| 2023 | -2.94% 617/2656 |
-2.51% 2003/2280 |
1.47% 215/2385 |
4.70% 133/2515 |
-6.28% 1702/2655 |
| 2022 | -4.58% 98/2207 |
2.26% 61/1919 |
-1.45% 1723/2016 |
-8.33% 191/2113 |
3.29% 729/2208 |
| 2021 | -1.53% 808/1822 |
9.89% 52/1255 |
-2.65% 1222/1330 |
-7.25% 1037/1466 |
-0.76% 1276/1822 |
| 2020 | 0.82% 936/1250 |
-13.55% 930/1028 |
2.20% 977/1067 |
4.80% 942/1164 |
8.88% 655/1184 |
| 2019 | 24.87% 610/1092 |
15.33% 687/754 |
2.38% 86/804 |
-0.68% 608/850 |
6.47% 606/918 |
| 2018 | -17.01% 123/834 |
- - |
- - |
- - |
-13.17% 512/691 |
| 2017 | 27.77% 83/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.09% 169/605 |
- - |
- - |
- - |
- - |
| 2015 | 1.18% 247/575 |
- - |
- - |
- - |
- - |
| 2014 | 52.44% 65/237 |
- - |
- - |
- - |
- - |
| 2013 | -8.99% 142/186 |
- - |
- - |
- - |
- - |
| 2012 | 13.24% 22/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝中证银行ETF联接A VS. 长安沪深300非周期A(740101) |